Sentence examples for benefit prediction from inspiring English sources

There are currently ongoing trials prospectively evaluating the Recurrence Score result and chemotherapy benefit prediction.

The improvement over GENSCAN and TWINSCAN demonstrates that the method can not only benefit prediction methods based on a single organism, but also benefit prediction methods based on comparative genomics.

In conclusion, we have shown that the BRCA1-like MLPA assay can be both applied in clinical genetic testing and in treatment benefit prediction.

In spite of the extensive scientific production no consensus on the use of a particular biomarker for therapy benefit prediction has been obtained.

For all benefit prediction functions, baseline patient status appeared to be a major benefit driver, and if a patient came to treatment when he or she was in a more serious status, changes in patient status between before and after treatments were likely to be larger (as would be expected from regression to the mean).

Use of the model might lead to more accurate absolute treatment benefit predictions for individual patients.

In CV1 and CV2, SG-UR gave prediction accuracies comparable to or less than that attained by SG-SR, suggesting that addition of residual covariance did not benefit predictions, and may have worsened them.

The model includes mode of detection and provides 5- and 10-year survival estimates as well as treatment benefit predictions at both time points, and it has been validated in an independent case cohort from the United Kingdom and more recently in a British Columbia data set wherein it was also compared with Adjuvant!

This is extremely important for optimal model function, as it is the breast cancer-specific mortality that is reduced by the relative risk reductions of adjuvant therapy, and this improvement in model performance by Predict+ should lead to more accurate absolute treatment benefit predictions for individual patients.

Various cost-benefit predictions for HS2 have been produced, but Lord Heseltine said these were "mumbo-jumbo".

The pool of available pharmacoeconomists is being depleted further, says Fendrick, as pharmaceutical companies shift toward ever earlier analyses of cost-benefit predictions during the drug discovery process.